Skip to main content
    D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $81.61
    -1.72 (-2.06%)

    Market Cap: $31.08B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    DexCom Inc (DXCM) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    DexCom (DXCM) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, DexCom reported EPS of $0.73, above the $0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +34.49%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.73
    Range$0.66 - $0.84
    28 analysts
    Revenue Consensus
    $1.41B
    Range$1.33B - $1.48B
    28 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.64
    Range$0.57 - $0.74
    17 analysts
    EPS Revisions
    2
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$0.64-1.0%
    60d ago$0.64+0.2%
    30d ago$0.64-0.7%
    7d ago$0.64-0.5%
    Current$0.64
    Revenue Consensus
    $1.31B
    Range$1.29B - $1.33B
    17 analysts

    Next Report

    DXCM has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.4% above the $0.68 reported for the quarter ended Dec 31, 2025.

    DXCM Earnings Call

    The latest DXCM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, DXCM beat 28, missed 7 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $1.34B, up 10.7% from $1.21B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.73$0.66$0.63 - $0.72+10.61%Beat+19.7%221 up, 1 downOct 29, 2026$1.34B
    Jun 30, 2026$0.70$0.61$0.57 - $0.66+14.75%Beat+45.8%2110 up, 4 downJul 30, 2026$1.31B
    Mar 31, 2026$0.56$0.47$0.42 - $0.53+19.15%Beat+75.0%211 up, 0 downApr 30, 2026$1.19B
    Dec 31, 2025$0.68$0.65$0.59 - $0.73+4.62%Beat+51.1%236 up, 1 downFeb 12, 2026$1.26B
    Sep 30, 2025$0.61$0.57$0.52 - $0.61+7.02%Beat+35.6%233 up, 0 downOct 30, 2025$1.21B
    Jun 30, 2025$0.48$0.44$0.42 - $0.49+9.09%Beat+11.6%231 up, 3 downJul 30, 2025$1.16B
    Mar 31, 2025$0.32$0.33$0.28 - $0.43-3.03%Miss0.0%221 up, 2 downMay 1, 2025$1.04B
    Dec 31, 2024$0.45$0.50$0.41 - $0.59-10.00%Miss-10.0%200 up, 8 downFeb 13, 2025$1.11B
    Sep 30, 2024$0.45$0.43$0.40 - $0.48+4.65%Beat-10.0%201 up, 0 downOct 24, 2024$994.20M
    Jun 30, 2024$0.43$0.39$0.34 - $0.42+10.26%Beat+26.5%200 up, 1 downJul 25, 2024$1.00B
    Mar 31, 2024$0.32$0.27$0.21 - $0.34+18.52%Beat+88.2%201 up, 0 downApr 25, 2024$921.00M
    Dec 31, 2023$0.50$0.43$0.37 - $0.48+16.28%Beat+47.1%185 up, 0 downFeb 8, 2024$1.03B
    Sep 30, 2023$0.50$0.33$0.26 - $0.46+51.52%Beat+78.6%190 up, 0 downOct 26, 2023$975.00M
    Jun 30, 2023$0.34$0.23$0.16 - $0.30+47.83%Beat+100.0%190 up, 0 downJul 27, 2023$871.30M
    Mar 31, 2023$0.17$0.15$0.08 - $0.20+13.33%Beat+112.5%180 up, 0 downApr 27, 2023$741.50M
    Dec 31, 2022$0.34$0.28$0.23 - $0.30+21.43%Beat+100.0%182 up, 0 downFeb 9, 2023$815.20M
    Sep 30, 2022$0.28$0.24$0.21 - $0.27+16.67%Beat+27.3%170 up, 1 downOct 27, 2022$769.60M
    Jun 30, 2022$0.17$0.19$0.13 - $0.25-10.53%Miss-10.5%170 up, 0 downJul 28, 2022$696.20M
    Mar 31, 2022$0.08$0.13$0.06 - $0.18-38.46%Miss0.0%170 up, 0 downApr 28, 2022$628.80M
    Dec 31, 2021$0.17$0.21$0.13 - $0.24-19.05%Miss-26.1%181 up, 0 downFeb 10, 2022$698.20M
    Sep 30, 2021$0.22$0.16$0.12 - $0.19+37.50%Beat-8.3%211 up, 0 downOct 28, 2021$650.20M
    Jun 30, 2021$0.19$0.11$0.06 - $0.16+72.73%Beat-5.0%21N/AJul 29, 2021$595.10M
    Mar 31, 2021$0.08$0.07$0.06 - $0.50+14.29%Beat-27.3%19N/AApr 29, 2021$505.00M
    Dec 31, 2020$0.23$0.23$0.18 - $0.280.00%In line-20.7%18N/AFeb 11, 2021$568.90M
    Sep 30, 2020$0.24$0.16$0.12 - $0.21+50.00%Beat+50.0%19N/AOct 27, 2020$500.90M
    Jun 30, 2020$0.20$0.09-$0.10 - $0.59+122.22%Beat+900.0%18N/AJul 28, 2020$451.80M
    Mar 31, 2020$0.11$0.04-$0.07 - $0.45+175.00%BeatN/A17N/AApr 28, 2020$405.10M
    Dec 31, 2019$0.29$0.18$0.14 - $0.25+61.11%Beat+107.1%17N/AFeb 13, 2020$462.80M
    Sep 30, 2019$0.16$0.20$0.08 - $0.34-20.00%Miss+300.0%17N/ANov 6, 2019$396.30M
    Jun 30, 2019$0.02$0.01-$0.12 - $0.17+100.00%BeatN/A16N/AJul 31, 2019$336.40M
    Mar 31, 2019-$0.01-$0.01-$0.44 - $0.180.00%In lineN/A16N/AMay 1, 2019$280.50M
    Dec 31, 2018$0.14$0.16$0.10 - $0.32-12.50%Miss+366.7%18N/AFeb 21, 2019$338.00M
    Sep 30, 2018$0.04-$0.02-$0.29 - $0.03+300.00%BeatN/A16N/ANov 6, 2018$266.70M
    Jun 30, 2018-$0.02-$0.04-$0.07 - -$0.02+50.00%BeatN/A19N/AAug 1, 2018$242.50M
    Mar 31, 2018-$0.08-$0.09-$0.51 - -$0.01+11.11%BeatN/A18N/AMay 2, 2018$184.40M
    Dec 31, 2017$0.03$0.01-$0.10 - $0.13+200.00%BeatN/A17N/AFeb 27, 2018$221.00M
    Sep 30, 2017-$0.01-$0.01N/A0.00%In lineN/A18N/ANov 1, 2017$184.60M
    Jun 30, 2017-$0.04-$0.06-$0.09 - -$0.03+33.33%BeatN/A16N/AAug 1, 2017$170.60M
    Mar 31, 2017-$0.12-$0.12N/A0.00%In lineN/AN/AN/AMay 2, 2017$142.30M
    Dec 31, 2016-$0.02-$0.02N/A0.00%In line-300.0%N/AN/AFeb 28, 2017$171.20M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.09, up 26.7% from the year before. It was -$0.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.09+26.7%
    Dec 31, 2024$1.65+9.3%
    Dec 31, 2023$1.51+73.6%
    Dec 31, 2022$0.87+31.8%
    Dec 31, 2021$0.66-15.4%
    Dec 31, 2020$0.78+69.6%
    Dec 31, 2019$0.46+475.0%
    Dec 31, 2018$0.08N/A
    Dec 31, 2017-$0.14N/A
    Dec 31, 2016-$0.19N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 19 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,68019
    2026Q2Jun 30, 20267,44519
    2026Q1Mar 31, 20268,71324
    2025Q4Dec 31, 20256,98820
    2025Q3Sep 30, 20259,29324
    2025Q2Jun 30, 20258,89523
    2025Q1Mar 31, 20259,13525
    2024Q4Dec 31, 202411,45424

    2026Q3 Earnings Call

    Opening remarks

    Sean Christensen Senior Vice President of Finance and Investor Relations Thank you, operator, and welcome to Dexcom's Third Quarter 2026 Earnings Call. Our agenda begins with Jake Leach, Dexcom's President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Operating Officer and Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter 2026 performance on the Dexcom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some statements on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. These statements are made as of the date hereof based on information currently available to Dexcom and are subject to various risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please see Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any forward-looking statement or to conform any forward-looking statements to actual results. Additionally, during the call, we will discuss certain non-GAAP financial measures. Unless otherwise noted, all financial measures discussed on this call are presented on a non-GAAP basis. Non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Please refer to the tables in our earnings release and the slides accompanying our third quarter 2026 earnings call for reconciliations to the most directly comparable GAAP measure. Now I will turn it over to Jake.

    Jacob Leach President and CEO Thank you, Sean, and thank you, everyone, for joining us. Today, we reported third quarter revenue growth of 11% compared to the third quarter of 2025 on both a reported and organic basis. Underlying our third quarter results are four key areas that advance our long-term vision we provided earlier this year. First, we continue to see strong momentum across the CGM category, driving our stable low double-digit revenue growth with active base growth above those levels. We once again gained share in the quarter, supported by prescriber and customer preference for Dexcom CGM, positioning us well as we prepare for significant access expansion. Second, our clinical evidence continues to strengthen the case for broader access to CGM.

    Frequently Asked Questions About DXCM

    When is DexCom's next earnings date?

    DexCom's next earnings report is expected for Feb 10, 2027.

    Did DXCM beat earnings estimates last quarter?

    Yes. DexCom reported EPS of $0.73 for the quarter ended Sep 30, 2026, above the $0.66 estimate, a 10.61% surprise.

    What EPS do analysts expect from DXCM next quarter?

    The consensus EPS estimate for DexCom for the quarter ending Dec 31, 2026 is $0.73 from 28 analysts, with estimates from $0.66 to $0.84.

    How often does DXCM beat earnings estimates?

    DexCom beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +6.53%.